Randomized Trial of Thymoglobulin Versus Alemtuzumab (with Lower Dose Maintenance Immunosuppression) Versus Daclizumab in Living Donor Renal Transplantation

Interleukin-2–Receptor Blockade with Daclizumab to Prevent Acute Rejection in Renal Transplantation

F. Vincenti, Robert L. Kirkman, Susan Light et al. · New England Journal of Medicine · 1998 · 876 citations · Full text

Medicine, Immunology, Pharmacology +17

REDUCTION OF THE OCCURRENCE OF ACUTE CELLULAR REJECTION AMONG RENAL ALLOGRAFT RECIPIENTS TREATED WITH BASILIXIMAB, A CHIMERIC ANTI-INTERLEUKIN-2-RECEPTOR MONOCLONAL ANTIBODY1,2

Barry D. Kahan, P. R. Rajagopalan, Michael Hall · Transplantation · 1999 · 483 citations

Life Sciences, Immunology, Pharmacology +17

Campath-1H Induction Plus Rapamycin Monotherapy for Renal Transplantation: Results of a Pilot Study

Stuart J. Knechtle, John D. Pirsch, John H. Fechner et al. · American Journal of Transplantation · 2003 · 380 citations · Full text

Life Sciences, Immunology, Pharmacotherapy +17

RESULTS OF THE DOUBLE-BLIND, RANDOMIZED, MULTICENTER, PHASE III CLINICAL TRIAL OF THYMOGLOBULIN VERSUS ATGAM IN THE TREATMENT OF ACUTE GRAFT REJECTION EPISODES AFTER RENAL TRANSPLANTATION1,2

A. Osama Gaber, M. Roy First, Raymond J. Tesi et al. · Transplantation · 1998 · 301 citations

Life Sciences, Immunology, Nephrology +17

A prospective, randomized, clinical trial of intraoperative versus postoperative thymoglobulin in adult cadaveric renal transplant recipients1

William C. Goggins, Manuel Pascual, John A. Powelson et al. · Transplantation · 2003 · 244 citations

Medicine, Nephrology, Surgery +17